Skip to content

A Pan-European Study on Minimally Invasive Versus Open Pancreatoduodenectomy in High-volume Centers

Outcomes After Minimally Invasive or Open Pancreatoduodenectomy in High-volume Centers; a Pan-European Retrospective Propensity-score Matched Cohort Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03172572
Acronym
MI-PD
Enrollment
4220
Registered
2017-06-01
Start date
2017-02-01
Completion date
2018-04-30
Last updated
2018-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreas Cancer, Pancreas Cyst, Pancreatic Neoplasms

Keywords

minimally invasive surgical procedures, pancreas surgery, pancreatoduodenectomy

Brief summary

RATIONALE: Minimally-invasive pancreatoduodenectomy (MIPD), either laparoscopic or robot-assisted, has been suggested as a valuable alternative to open pancreatoduodenectomy (OPD). The generalizability of the current literature is, however, unknown since randomized studies are lacking, and current data are published from few, very high volume centers and selection bias with a lack of case-matched series. International studies are lacking completely. OBJECTIVE: To compare outcomes of MIPD versus open pancreatoduodenectomy (OPD), in high-volume European pancreas centers (\>10 MIPDs per year, total \>20 PDs per year). METHODS: A retrospective multicenter propensity-score matched cohort study including all consecutive patients who underwent MIPD (or MI total pancreatectomy) between January 2012 and December 2016, for pancreatic head, bile duct, or duodenal cancer or cysts except chronic pancreatitis. Predefined electronic case report forms will be disseminated amongst participating centers. Participants are responsible for their own data collection. Matching of MIPD cases (collected from participating centers) to OPD controls (extracted from Dutch and German national registries) will be based on propensity scores determined by logistic regression including preoperative variables: year of surgery, demographics, BMI, ASA, comorbidities, tumor size, tumor etiology (diagnosis), and multivisceral resection. Primary outcome is 90-day major morbidity(Clavien-Dindo ≥ 3a). Secondary outcomes are 90-day postoperative events including: pancreatic fistula, length of hospital stay, R0 (microscopically negative) resection margin, malignant lymph node ratio, days to adjuvant therapy and overall survival.

Interventions

Laparoscopic, robot-assisted, or hybrid resection

Open resection

Sponsors

S (Sjors) Klompmaker, MD
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Indication for open or minimally invasive pancreatoduodenectomy * Pancreatic head, bile duct, or duodenal cancer or cysts

Exclusion criteria

* Chronic pancreatitis without suspected solid tumor.

Design outcomes

Primary

MeasureTime frameDescription
Major morbidity90-daysClavien-Dindo grade 3a-5 complications

Secondary

MeasureTime frameDescription
Pancreatic fistulae90-daysISGPS 2017 definition
Length of stay90-dayslength of hospital stay
Radical resection rate90-daysR0/R1/R2 classification
Malignant lymph node ratio90-daysMalignant/ non-malignant lymph nodes
time to adjuvant therapy90-daysResection to adjuvant chemo(-radio) therapy
Overall survival90-days

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026